AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14600516
Drug: Simplified maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified maintenance therapy (SMT)
Trial: 14600516
Drug: Continued protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued protease inhibitor (PI) therapy
Trial: 1824248
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (MTX)
Trial: 6850612
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapy (Nocardia rubra cell wall skeleton, 400 micrograms, intradermal injection weekly for the first month and monthly thereafter)
Trial: 30211721
Drug: Combined mirror
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mirror and extracorporeal shock wave therapy (ESWT)
Trial: 24331545
Drug: Low field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low field magnetic stimulation (LFMS), single 20-minute treatment
Trial: 22176629
Drug: Posaconazole 50
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 50 mg
Trial: 22176629
Drug: Posaconazole 100
RxNorm normalized name: posaconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 100 mg
Trial: 22176629
Drug: Posaconazole 200
RxNorm normalized name: posaconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 200 mg
Trial: 17373918
Drug: Hyperhomocysteinaemia (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperhomocysteinaemia (high homocysteine level >15 micromol/L)
Trial: 15829804
Drug: Topical itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical itraconazole 1%
Trial: 12102671
Drug: Levetiracetam, 500
RxNorm normalized name: LevETIRAcetam, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam, 500 mg, twice daily
Trial: 7605860
Drug: Levosulpiride 25
RxNorm normalized name: Levosulpiride 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride 25 mg t.d.s. for 4 weeks
Trial: 2369474
Drug: Intravesical application
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical application of cephalotin in saline solution
Trial: 22018220
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution only (control group)
Trial: 31692188
Drug: galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: galcanezumab 120 mg
Trial: 31692188
Drug: galcanezumab 240
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: galcanezumab 240 mg
Trial: 19559427
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL cyanoacrylate injection (group A)
Trial: 19559427
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL cyanoacrylate injection (group B)
Trial: 11578673
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosing (SDD) of antidepressants
Trial: 11578673
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily dosing (MDD) of antidepressants
Trial: 8147945
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 mg slow release tablet, Aprical long)
Trial: 3260059
Drug: Walking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking therapy
Trial: 3260059
Drug: Sauna therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sauna therapy
Trial: 23782948
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate, large isocaloric doses, duration 8 weeks
Trial: 23782948
Drug: Rice protein
RxNorm normalized name: rice protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice protein isolate, large isocaloric doses, duration 8 weeks
Trial: 15176685
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg b.i.d. for 8 weeks (Arm A)
Trial: 15176685
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg t.i.d. (Arm B)
Trial: 15176685
Drug: Placebo dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dextrose tablets (Arm C)
Trial: 12738555
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol
Trial: 11528262
Drug: Topical apraclonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical apraclonidine
Trial: 9437230
Drug: GLP-1 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (400 micrograms buccal tablet)
Trial: 3828171
Drug: Closed-loop computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop computer system delivering sodium nitroprusside infusion
Trial: 12593178
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education programs for asthma; details on dosage and duration not specified.
Trial: 12593178
Drug: Education programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education programs in COPD including self-management; details on dosage and duration not specified.
Trial: 12593178
Drug: Cost effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost effectiveness of education programs for asthmatics; details on dosage and duration not specified.
Trial: 10636350
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of cefotaxime sodium diluted in 100 mL of isotonic sodium chloride solution (Group A)
Trial: 10636350
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of isotonic sodium chloride solution in 100 mL of saline (Group B)
Trial: 4041323
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine solution 4 ml without glucose
Trial: 4041323
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine solution 4 ml with glucose
Trial: 24935040
Drug: Intramyocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injection of mobilized BMSCs
Trial: 24935040
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of mobilized BMSCs
Trial: 24935040
Drug: Subcutaneous granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous granulocyte colony-stimulating factor injections
Trial: 24935040
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections only
Trial: 20400900
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 250 mg aspirin
Trial: 8648016
Drug: Azelastine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (4 mg twice daily)
Trial: 17239638
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelastine and montelukast
Trial: 15315030
Drug: Azithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg once a week
Trial: 27583108
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (Group A)
Trial: 18952538
Drug: OAT (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAT (omeprazole, amoxicillin, tinidazole)
Trial: 17366797
Drug: Radiotherapy (LCAHFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (LCAHFR with total dose of 68.4-71.0 Gy)
Trial: 11064608
Drug: Lidocaine 20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20.0 mg in 2.0 ml
Trial: 11064608
Drug: Ketamine 5
RxNorm normalized name: ketamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 5 mg in 2.0 ml
Trial: 11064608
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 2.0 ml
Trial: 31977667
Drug: Low-dose estradiol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estradiol
Trial: 31977667
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol tablet
Trial: 20200432
Drug: Antioxidant micronutrient
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant micronutrient combination (800 mg dl‐alpha‐tocopherol acetate, 24 mg beta‐carotene, 1.0 g vitamin C, 200 microg l‐selenomethionine, 7.2 mg riboflavin, 80 mg niacin, 60 mg zinc, 5 mg manganese) given daily over 4 months
Trial: 20200432
Drug: Antioxidant micronutrient
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant micronutrient combination
Trial: 10499750
Drug: Neostigmine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (500 microg) + mepivacaine (500 mg)
Trial: 10499750
Drug: Mepivacaine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (500 mg) + saline (0.9%, 1 mL)
Trial: 6407402
Drug: Benoxaprofen 600
RxNorm normalized name: fenoprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 600 mg orally daily for 8 weeks
Trial: 24920891
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP; 500 μg twice daily for 6 months)
Trial: 20962624
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (HD-IVIG)
Trial: 20962624
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous immunoglobulin (low-IVIG)
Trial: 11114219
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d OXC
Trial: 11114219
Drug: 1200 mg/d
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/d OXC
Trial: 11114219
Drug: 2400 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/d OXC
Trial: 8788262
Drug: Dietary fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fish oil (FO) supplementation (5 food bars daily for 6 weeks)
Trial: 1638170
Drug: brofaromine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brofaromine (150 mg daily)
Trial: 6465821
Drug: Intravenous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous indomethacin (50 mg)
Trial: 6465821
Drug: Intravenous metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metamizole (2.5 g)
Trial: 20463564
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (methylprednisolone)
Trial: 29868796
Drug: Ozone (O2‐O3)
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (O2‐O3) injection
Trial: 21477416
Drug: Quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine IR (300 mg/d on days 9-12)
Trial: 21477416
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (300 mg/d on days 5-8)
Trial: 19500999
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Pro‐Stat 64 supplementation
Trial: 19500999
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of Pro‐Stat 64 supplementation
Trial: 16518128
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of methylphenidate
Trial: 11020910
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg mesulid, Pfizer)
Trial: 11020910
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg, Bayer)
Trial: 9025767
Drug: MP therapy
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP therapy (MPH/PSL combination)
Trial: 9025767
Drug: AT (alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT (alternating therapy with VMCP and MMPP)
Trial: 8331248
Drug: Betaxolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.25% ophthalmic suspension (preserved with benzalkonium chloride)
Trial: 8331248
Drug: Betaxolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.25% ophthalmic suspension (unpreserved)
Trial: 3579256
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg every 6 h (five doses)
Trial: 3579256
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg every 12 h (three doses)
Trial: 28666964
Drug: Fournier® 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fournier® 200 mg capsule
Trial: 28666964
Drug: Lipidil® 145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipidil® 145 mg tablet
Trial: 28666964
Drug: HME 160
RxNorm normalized name: TRACH-VENT HME TELEFLEX #41112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HME 160 mg tablet
Trial: 27629349
Drug: Extracellular space
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracellular space contrast agents (ECSCAs)
Trial: 27629349
Drug: Blood-pool contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-pool contrast agent (BPCA)
Trial: 24429305
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment arm (ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment)
Trial: 24429305
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment arm (ART after completing anti-tuberculosis treatment)
Trial: 22395586
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of essential oil of Melaleuca alternifolia and organically bound iodine (TTO-I)
Trial: 10550740
Drug: sublingual‐swallow immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual‐swallow immunotherapy
Trial: 8889480
Drug: H-wave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-wave therapy at 16 Hz
Trial: 10583337
Drug: H-wave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-wave therapy at 60 Hz
Trial: 10583337
Drug: H-wave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-wave therapy at 2 Hz
Trial: 25724644
Drug: Pradigastat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat (100 mg for 3 days followed by 40 mg for 7 days, 1 hour before meal)
Trial: 24582486
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 2 mg/mL per min) plus paclitaxel (60 mg/m(2)) every week for 18 weeks
Trial: 24582486
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 6 mg/mL per min) plus paclitaxel (175 mg/m(2)) every 3 weeks for six cycles
Trial: 15507885
Drug: Oral defibrotide
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral defibrotide (800 mg/die)
Trial: 11331472
Drug: Imipenem (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (1.0 g plus cilastatin intravenously 3 times a day)
Trial: 11331472
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (delayed antibiotics)
Trial: 9425396
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant growth hormone (rhGH) replacement therapy at a dosage of 12.5 micrograms/kg/day (initial dosage during the first 4 weeks 6.25 micrograms/kg/day)
Trial: 8245105
Drug: Non-acid-buffering prophylaxis
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-acid-buffering prophylaxis therapy (6 patients)
Trial: 8245105
Drug: Standard antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antacid or antacid/H2 histamine-blocking agent combination prophylaxis therapy (13 patients)
Trial: 25362221
Drug: Raloxifene, 60
RxNorm normalized name: Raloxifene, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene, 60 mg/d for 8 months
Trial: 11979650
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin (Bactroban) applied to nares and catheter exit site
Trial: 10023498
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 100 mg
Trial: 10023498
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 250 mg
Trial: 10023498
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 500 mg
Trial: 7751428
Drug: Local phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local phentolamine (administered directly into a preconstricted hand vein)
Trial: 7751428
Drug: Systemic phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic phentolamine (administered intravenously)
Trial: 7751428
Drug: Control (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (vehicle solutions)
Trial: 43755
Drug: Metoclopramide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 40 mg
Trial: 27595728
Drug: 5% EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% EMLA cream
Trial: 23370902
Drug: 0.5-mg intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg intravitreal ranibizumab
Trial: 21550313
Drug: Cefotaxime infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime infusion plus paracetamol
Trial: 21550313
Drug: Cefotaxime infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime infusion
Trial: 21550313
Drug: Cefotaxime bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime bolus plus paracetamol
Trial: 19189066
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin (AT) without simultaneous heparin treatment
Trial: 19189066
Drug: High-dose antithrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithrombin (AT) without simultaneous heparin treatment in risk group grade II patients
Trial: 17536000
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at 0.06 mg/kg.d for 2 years (group I)
Trial: 17536000
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) for 12 months after 12 months of no treatment (group II)
Trial: 14990550
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg of 0.9% NaCl infusion over 60 min
Trial: 19459553
Drug: Ropivacaine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (150 mg)
Trial: 11810323
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg or 5 mg)
Trial: 11810323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5 mg morphine and 75 mg ropivacaine
Trial: 9732164
Drug: ebastine 10
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebastine 10 mg
Trial: 8054406
Drug: Lisuride (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (up to 4.0 mg daily for 3 weeks)
Trial: 26510448
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily for 24 weeks